Last Updated on October 15, 2024 by The Health Master
Mumbai: Glenmark Specialty SA, the subsidiary of Glenmark Pharmaceuticals Ltd has received acceptance from the US Food and Drug Administration (USFDA) on its Investigational New Drug (IND) application for GRC 54276 to proceed with a Phase 1/2 human clinical study in India, to evaluate the drug’s safety, tolerability, pharmacokinetics and preliminary anti-tumour activity.
GRC 54276, an orally available, small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, is being tested to assess its efficacy for treating patients with advanced solid tumours and lymphomas.
HPK1-regulated functions are involved in nearly every step of the cancer-immunity cycle making it an attractive target for immuno-oncology.
By inhibiting HPK1, GRC 54276 is designed to potentially enhance the patient’s own immune system to fight cancers.
GRC 54276 is being studied as monotherapy or in combination with Anti PD-1 or Anti PDL-1 therapy in adults with advanced solid tumours and lymphomas.
To date, 16 patients with various types of advanced cancers have been enrolled in this ongoing study in India, and the company plans to expand the study at ex-India research sites in the subsequent months.
Commenting on the approval, Nikhil Amin, Chief scientific officer and President, Innovative Medicine Group, Glenmark Pharmaceuticals Ltd. said, “Now that the USFDA has accepted our IND application, we look forward to initiating the ongoing Phase 1/2 study at the US sites.”
“We are excited about the prospects of what this new class of immune-oncology medicines may mean for patients in need.”
Forms: All types of Clinical Trials
Schedules: All types of Clinical Trials
Notifications: New Drugs, FDC, Clinical Trial
Other details about New Drugs, FDCs, Clinical trial
Target to reduce dependence on imported raw materials: Recommendation
SC: Doctor can’t be punished under D&C Act for storing small quantities of medicines
Govt adds six rare diseases under National Policy for Rare Diseases
Delhi High Court asks Centre to file status report on sale medicines online
Govt amends New Drugs and Clinical Trials Rules, 2019
Guidelines on medical negligence under consideration
NEET PG 2023 result out | Direct link to check
NMC directs all medical colleges to get them enrolled with IPC
Difference between branded and generic medicines
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
